ATE237687T1 - Rekombinierte sequenzen des monoklonalen anti- idiotypischen antikörpers 3h1, diean dem menschlichen karzioembyonischen antigen liiert sind - Google Patents

Rekombinierte sequenzen des monoklonalen anti- idiotypischen antikörpers 3h1, diean dem menschlichen karzioembyonischen antigen liiert sind

Info

Publication number
ATE237687T1
ATE237687T1 AT95944450T AT95944450T ATE237687T1 AT E237687 T1 ATE237687 T1 AT E237687T1 AT 95944450 T AT95944450 T AT 95944450T AT 95944450 T AT95944450 T AT 95944450T AT E237687 T1 ATE237687 T1 AT E237687T1
Authority
AT
Austria
Prior art keywords
antigen
monoclonal
carcioembyonic
linked
human
Prior art date
Application number
AT95944450T
Other languages
English (en)
Inventor
Malaya Chatterjee
Heinz Kohler
Sunil K Chatterjee
Kenneth A Foon
Original Assignee
Univ Kentucky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky filed Critical Univ Kentucky
Application granted granted Critical
Publication of ATE237687T1 publication Critical patent/ATE237687T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95944450T 1994-12-28 1995-12-28 Rekombinierte sequenzen des monoklonalen anti- idiotypischen antikörpers 3h1, diean dem menschlichen karzioembyonischen antigen liiert sind ATE237687T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36548494A 1994-12-28 1994-12-28
PCT/US1995/017103 WO1996020277A2 (en) 1994-12-28 1995-12-28 Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen

Publications (1)

Publication Number Publication Date
ATE237687T1 true ATE237687T1 (de) 2003-05-15

Family

ID=23439088

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95944582T ATE235514T1 (de) 1994-12-28 1995-12-28 Monoklonaler anti-idiotypischer antikörper 3h1 aus maus
AT95944450T ATE237687T1 (de) 1994-12-28 1995-12-28 Rekombinierte sequenzen des monoklonalen anti- idiotypischen antikörpers 3h1, diean dem menschlichen karzioembyonischen antigen liiert sind

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95944582T ATE235514T1 (de) 1994-12-28 1995-12-28 Monoklonaler anti-idiotypischer antikörper 3h1 aus maus

Country Status (12)

Country Link
US (3) US5977315A (de)
EP (3) EP1298144A3 (de)
JP (2) JPH10511846A (de)
AT (2) ATE235514T1 (de)
AU (2) AU704829B2 (de)
CA (2) CA2209360C (de)
DE (2) DE69530107T2 (de)
DK (2) DK0796280T3 (de)
ES (2) ES2197217T3 (de)
MX (2) MX9704897A (de)
PT (2) PT796280E (de)
WO (2) WO1996020219A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2197217T3 (es) * 1994-12-28 2004-01-01 University Of Kentucky Research Foundation Anticuerpo 3h1 monoclonal anti-id-murino.
US6235280B1 (en) * 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US20020041872A1 (en) 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
WO1997042973A1 (en) * 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US20020098190A1 (en) * 1997-06-13 2002-07-25 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
NZ501990A (en) * 1997-07-08 2002-09-27 Viventia Biotech Inc Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody
US7569674B2 (en) 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
US6774209B1 (en) * 2000-04-03 2004-08-10 Dyax Corp. Binding peptides for carcinoembryonic antigen (CEA)
US8101200B2 (en) 2000-04-13 2012-01-24 Angiotech Biocoatings, Inc. Targeted therapeutic agent release devices and methods of making and using the same
US20020139628A1 (en) * 2001-03-30 2002-10-03 Wen-Chen Chang Retractable handle assembly
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
AT500650B1 (de) * 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
KR20070051848A (ko) * 2004-08-05 2007-05-18 알 앤 디 그린 머티리얼, 엘엘씨 고체 생분해성 제품 제조를 위한 저온 몰딩 방법
CA2589009A1 (en) * 2004-11-24 2006-06-01 Health Research Inc. Method for identifying and designing immunogenic peptides
TW200732346A (en) * 2005-10-13 2007-09-01 Virexx Medical Corp Chimeric hepatitis C virus antigens for eliciting an immune response
EP1999153B1 (de) * 2006-03-29 2014-04-23 King's College London Agonistische antikörper gegen tshr
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
CN101854946B (zh) 2007-11-08 2013-07-03 尼尔詹尼克斯肿瘤研究公司 结肠癌和胰腺癌的重组单克隆抗体和相应抗原
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
MX2012004877A (es) 2009-10-26 2012-05-23 Prometheus Lab Inc Analisis para la deteccion de farmacos anti-tnf y autoanticuerpos.
SG189391A1 (en) 2010-10-18 2013-05-31 Nestec Sa Methods for determining anti-drug antibody isotypes
AU2012278802B2 (en) 2011-07-06 2015-11-26 Société des Produits Nestlé S.A. Assays for detecting neutralizing autoantibodies to biologic therapy with TNF alpha
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
JP2018500553A (ja) 2014-12-05 2018-01-11 ネステク ソシエテ アノニム 患者試料における生物製剤の検出のための間接的均一移動度シフトアッセイ
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
CN119708155B (zh) * 2024-12-30 2025-12-09 中国药科大学 地龙抗血小板寡肽及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4436728A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5053224A (en) 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
EP0291636A1 (de) 1983-11-07 1988-11-23 The Wistar Institute Von Anti-Idiotyp-Antikörpern induzierte Immunreaktion gegen Viren
US5180814A (en) 1984-01-31 1993-01-19 Akzo N.V. Tumor specific monoclonal antibodies
US5106738A (en) 1984-01-31 1992-04-21 Akzo Nv Tumor specific monoclonal antibodies
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5160723A (en) 1985-04-19 1992-11-03 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
GB2202017A (en) * 1987-03-07 1988-09-14 Alvan Michael Judson Anti-lock electric braking
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2517343B2 (ja) * 1988-01-26 1996-07-24 富士写真フイルム株式会社 熱現像感光材料
JPH01207920A (ja) 1988-02-16 1989-08-21 Oki Electric Ind Co Ltd ＩｎＰ半導体薄膜の製造方法
GB8812137D0 (en) 1988-05-23 1988-06-29 Imp Cancer Res Tech Antibodies
US5183756A (en) 1988-08-19 1993-02-02 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody (D612) having selective reactivity for gastrointestinal caricinomas and method for employing the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5407684A (en) 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5077284A (en) * 1988-12-30 1991-12-31 Loria Roger M Use of dehydroepiandrosterone to improve immune response
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5244801A (en) 1989-12-28 1993-09-14 Martin Tobi Process for producing monoclonal antibodies which specifically bind to benign colonic adenomatous polyps of human origin and hybridomas and monoclonal antibodies produced by said process
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
US5200316A (en) 1990-02-15 1993-04-06 Miles Inc. Immunoassay methods using noncross reactive cea gene family members antibodies
WO1991016924A1 (en) 1990-05-10 1991-11-14 The Dana-Farber Cancer Institute Enhancing the association of exogenous peptides with class i mhc molecules on immune system cells
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
AU2690192A (en) 1991-09-19 1993-04-27 Lionel A. Manson Tumor immunotherapy utilizing a method of overcoming the resistance of a progressively growing tumor
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
WO1994005329A1 (en) 1992-08-31 1994-03-17 Jenner Technologies Stimulation of an antitumor t-cell response using anti-idiotypic antibodies
ES2197217T3 (es) * 1994-12-28 2004-01-01 University Of Kentucky Research Foundation Anticuerpo 3h1 monoclonal anti-id-murino.

Also Published As

Publication number Publication date
US20010047083A1 (en) 2001-11-29
AU717779B2 (en) 2000-03-30
DK0796280T3 (da) 2003-04-22
JPH10511846A (ja) 1998-11-17
DE69530107D1 (de) 2003-04-30
DK0800578T3 (da) 2003-08-11
WO1996020219A3 (en) 1996-09-06
DE69530107T2 (de) 2003-10-16
ES2196098T3 (es) 2003-12-16
EP1298144A2 (de) 2003-04-02
MX9704898A (es) 1998-06-28
EP0800578A2 (de) 1997-10-15
WO1996020277A2 (en) 1996-07-04
PT796280E (pt) 2003-08-29
CA2209360C (en) 2010-07-06
EP1298144A3 (de) 2006-05-31
JPH11500607A (ja) 1999-01-19
WO1996020277A3 (en) 1996-09-06
MX9704897A (es) 1998-06-28
AU4692796A (en) 1996-07-19
DE69530415D1 (de) 2003-05-22
AU704829B2 (en) 1999-05-06
DE69530415T2 (de) 2004-02-12
ATE235514T1 (de) 2003-04-15
CA2209172A1 (en) 1996-07-04
CA2209360A1 (en) 1996-07-04
US5977315A (en) 1999-11-02
PT800578E (pt) 2003-09-30
ES2197217T3 (es) 2004-01-01
US7090842B1 (en) 2006-08-15
CA2209172C (en) 2007-04-10
WO1996020219A2 (en) 1996-07-04
EP0796280A2 (de) 1997-09-24
EP0796280B1 (de) 2003-03-26
EP0800578B1 (de) 2003-04-16
AU717779C (en) 2002-12-05
AU4649896A (en) 1996-07-19

Similar Documents

Publication Publication Date Title
ATE237687T1 (de) Rekombinierte sequenzen des monoklonalen anti- idiotypischen antikörpers 3h1, diean dem menschlichen karzioembyonischen antigen liiert sind
DE69635843D1 (de) Monoklonaler anti-idiotypischer antikörper 11d10 aus der maus und methoden zu dessen verwendung
EP0966485A4 (de) Mutierte nicht aktivierende igg2 domäne und diese sequenz enthaltende anti-cd3 antikörper
DE3574730D1 (de) Monoklonaler antikoerper gegen ein humanes tumor-karzinom-assoziiertes antigen.
DE69434475D1 (de) Impfstoff gegen prostatakrebs
ATE397456T1 (de) Enterokokkus antigene und vakzine
WO1999041383A8 (en) Antigen library immunization
DE3783277D1 (de) Monoklonaler antikoerper gegen humanes lungenkarzinom.
EP0552296A4 (en) Mouse monoclonal antibodies
DK0473721T3 (da) Antiidiotypisk antistof, som fremkalder en immunreaktion med et glycosphingolipid, og anvendelse deraf
ITRM920457A0 (it) Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteinaumana.
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
EP1379270A4 (de) Verfahren zur induzierung von immuntoleranz
ID20117A (id) Antibodi anti-fas
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
FI924576A0 (fi) Ctaa 28a32, antigen identiefierad av mca 28a32
ZA884777B (en) Antigen recognized by mca 16 88
WO1998027999A3 (de) Zusammensetzungen zur behandlung von immunerkrankungen die haptenisierte antigen-antikörper komplexe enthalten
EP1555316A3 (de) Antigenbibliothek Immunisierung
FI925638A7 (fi) Kasvainten yhteydessä esiintyvää antigeenia vastaan suunnattu monoklonaalinen vasta-aine 88BV59

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0800578

Country of ref document: EP

REN Ceased due to non-payment of the annual fee